AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flow cytometry
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01413022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04136309
Study NCT03269513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
Study NCT02220218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)
Description: Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
Study NCT02220218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
Study NCT02220218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin IR
Description: Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
Study NCT01867970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tool
Description: The It's LiFe! tool consists of three different elements:~1. the 3D accelerometer (Figure 7-8);~2. the application (app) on a Samsung Smartphone (Figure 6);~3. a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription.
Study NCT01867970 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management Support Program
Description: Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
Study NCT04185922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: As stated in Hemopatch arm description
Study NCT00279877 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: kyphoplasty
Study NCT03462537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes.
Study NCT03462537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Aerobic exercise protocol - 50 minutes of aerobic moderate-intensity exercise (45-55% of reserve heart rate) using Karvonen´s formula, performed on a cycloergometer. The duration of the exercise was divided into three parts: warm-up (from 0 to 5 minutes); body (from 5 to 45 minutes); and cooling (from 45 to 50 minutes). The entire protocol was monitored through the Polar® brand cardiofrequency and watch.
Study NCT03462537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy without power
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
Study NCT03462537 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low level laser therapy without power
Description: Low level laser therapy protocol - The low level laser therapy protocol was performed in dorsal decubitus, with the head elevated at 45º. The electrodes were placed in line, in the abdominal region. The low level laser therapy device has a length of about 940nm, using 8 pads, which have 64 diodes, each one with 100mW. The duration of the application was established in 8 minutes. In this group low level laser therapy device was switched off.
Study NCT01940783 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
Study NCT01940783 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: One pre-operative (before cochlear implantation) MRI scan of the cochlea.
Study NCT02658175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Description: 300 mg volanesorsen administered via SC injection.
Study NCT00895388 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured Rehabilitation program
Description: Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
Study NCT02554383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
Study NCT02554383 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo made to match the study antibiotic given twice a day orally for 10 days
Study NCT02194829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: Given PO
Study NCT02194829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT02194829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT01185171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD 1839 500mg
Description: Optional Induction chemotherapy:~Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance \[CC\] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.~Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle.
Study NCT01040715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNFa Kinoid
Description: TNFa kinoid
Study NCT01040715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNF kinoid
Description: IM administration 2 or 3 injections within 28 days
Study NCT02960477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience education
Description: A PNE session covers the neurobiology, neurophysiology and processing of pain.
Study NCT02960477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomedical Education
Description: A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
Study NCT02536781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Anti-inflammation gel
Study NCT02536781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank gel
Study NCT03623633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: denosumab
Description: denosumab 60 milligrams subcutaneously every 6 months
Study NCT03623633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: alendronate 70 milligrams weekly
Study NCT03623633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: raloxifene 60 milligrams daily
Study NCT02869841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine continuous infusion
Description: Levobupivacaine continuous infusion to rectus sheath catheters
Study NCT02869841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine bolus dosing
Description: Levobupivacaine bolus dosing to rectus sheath catheters
Study NCT02869841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single bolus of levobupivacaine
Description: Levobupivacaine single dose to rectus sheath catheters
Study NCT02869841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No rectus sheath analgesia
Study NCT02097459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Study NCT02097459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Study NCT02097459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Study NCT02097459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Study NCT02097459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toremifene
Study NCT00938587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 10 mg
Description: PF-04171327 10 mg tablet every day for 14 days
Study NCT00938587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prednisone Placebo
Description: Placebo for Prednisone 5 mg tablet every day for 14 days
Study NCT00938587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327 25 mg
Description: PF-04171327 25 mg tablet every day for 14 days
Study NCT00938587 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 5 mg
Description: Prednisone 5 mg tablet every day for 14 days
Study NCT00938587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for PF-04171327
Description: Placebo for PF-04171327 every day for 14 days
Study NCT00938587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet every day for 14 days
Study NCT00938587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PF-04171327
Description: Placebo tablet every day for 14 days
Study NCT01938989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Clear clip-on glasses
Description: Clip-on glasses with no light filtering properties
Study NCT01938989 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Blue light filter clip-on glasses
Description: Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
Study NCT04064255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practical Body Image (session 1 - 7)
Description: Practical body image therapy
Study NCT04064255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practical Body Image (session 8 - 14)
Description: Twice weekly mirror exposure plus ending session
Study NCT04441385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg
Description: Patients will receive maraviroc 300 mg twice daily for 14 days
Study NCT04441385 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care therapy
Description: Subjects randomized to control group will be on standard care treatment according to the Ministry of Health and Local Guidelines and Protocols.
Study NCT01354548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBite® Jaw Motion Rehabilitation System™
Description: A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
Study NCT00933114 — intervention group
Intervention type: PROCEDURE
Intervention: MRI and PET imaging
Description: Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
Study NCT04877158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Blame and Perspective-Taking Intervention
Description: The intervention is a group therapy that consists of experiential art tasks followed by psychoeducation about social behaviors with weekly homework. There are four sessions, each one week apart.
Study NCT01715142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
Study NCT01977027 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Alternate Hand Training or Affected Hand Training
Description: Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
Study NCT01818609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step reduction
Description: taking less than 1500 steps/d
Study NCT00715117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
Study NCT00715117 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, sugar pill
Description: Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
Study NCT02394522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Repellent product with active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator
Study NCT02394522 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Ingredient
Description: Transfluthrin (Active ingredient)
Study NCT02394522 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spatial Repellent product without active ingredient (SHIELD)
Description: Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
Study NCT02997683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Vibration platform GALILEO
Description: 3 month home based training on whole Body Vibration platform GALILEO
Study NCT02997683 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: exercises at home on the floor
Description: exercises at home on the floor
Study NCT02576327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)
Study NCT02576327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tropisetron
Description: Tropisetron Hydrochloride Injection 5mg (Day 1-6)
Study NCT02576327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
Study NCT02576327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
Study NCT02576327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
Study NCT03774875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg tablets taken orally twice a day.
Study NCT03774875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Apremilast 30 mg tablets taken orally twice a day.
Study NCT03774875 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally twice a day
Study NCT00450398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
Study NCT00450398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
Study NCT05714423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-PCNL
Description: Mini-PCNL will done as follows. A 6 Fr ureteral catheter will be introduced through cystoscopy and dye will be instilled to opacify the pelvicalyceal system. After elaborating the calyceal system through fluoroscopy, selective calyceal will be punctured and tract will be dilated using 16 F sheath. Miniature nephroscope 14 Fr will be then introduced and stones will be fragmented by holmium: YAG laser. Afterwards the collecting system will be examined through nephroscope and fluoroscopic confirmation will be done to ensure complete stone clearance. In all the cases, 6 Fr 24 cm DJ stent will be placed and if remained uneventful, the patient will be discharged on postoperative day 2 with oral antibiotics.
Study NCT05714423 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS
Description: RIRS will be performed as follows. In this procedure a double J stent will be placed to dilate the calyceal system 2 weeks prior the surgery. During the procedure, cystoscopy will be done, and 0.035-inch guide wire will be placed in the pelvi-calyceal system. Ureteric access sheath of 12 Fr will be placed and with the help of digital polyscope the stone will be fragmented using Holmium: YAG laser using 220 μm fiber. DJ stent 6F 24 cm will be placed in all the cases. In uneventful surgery patient will be discharged on postoperative day 1 with oral antibiotics
Study NCT01018732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Novartis Meningococcal (MenACWY-CRM) vaccine
Description: All subjects will have blood draws at Day 1, Day 8, and Day 29.
Study NCT00398723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narrowband UVB
Description: Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema